Clinical Trial Update: A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects [Phase 3]

View source ↗

Summary

Phase 3a long-term safety study of mepolizumab in asthmatic subjects has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Mepolizumab (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2018-05-02